Randomized trial reveals improved analysis of 225Ac radiopharmaceuticals, suggesting enhanced quality control procedures.
Background Analytical data for 225 Ac-labeled radiopharmaceuticals are currently obtained using thin-layer chromatography and high-performance liquid chromatography, the latter followed by offline fraction collection and delayed gamma-counting after secular equilibrium with gamma-emitting daughters has been reached. These procedures are slow and do not depict the distribution of daughter radionuclides. An inline HPLC detection setup combining liquid scintillation detection and LaBr 3 -based gamma-spectroscopy is presented to enable faster and more informative analysis of a 225 Ac radiopharmaceutical. Results Four chromatographic signals were identified corresponding to uncomplexed 221 Fr with at most a minor contribution of free 213 Bi, [ 213 Bi]Bi-PSMA I&T, [ 225 Ac]Ac-PSMA I&T, and [ 209 Pb]Pb-PSMA I&T. The retention times corresponded to those of the non-radioactive analogs determined by UV detection. Assignments were confirmed by fraction collection followed by gamma-spectroscopy and beta liquid scintillation counting. The distribution of these species changed upon heating the reaction mixture or after addition of another ligand. Conclusions The combined detection setup enables rapid observation of isotope distribution and daughter behavior during chromatographic analysis and avoids fraction handling by operating as a closed system, thereby reducing contamination risk and radiation exposure. This approach may contribute to improved quality control procedures for 225 Ac radiopharmaceuticals and other alpha-emitting radionuclides. At the present stage, however, it should be regarded as a qualitative to semi-quantitative proof-of-principle.
No takes yet. Share an insight, caveat, or question.
Claude et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: